RA Capital Management, L.P. 13D and 13G filings for EyePoint Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:37 pm Purchase |
2024-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
RA Capital Management, L.P. | 3,181,818 4.700% |
86,682 (+2.80%) |
Filing |
| 2024-02-14 9:08 pm Sale |
2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
RA Capital Management, L.P. | 3,095,136 6.100% |
-313,570 (-9.20%) |
Filing |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
RA Capital Management, L.P. | 3,408,706 9.990% |
1,801,847 (+112.13%) |
Filing |
| 2021-08-13 4:31 pm Purchase |
2021-08-03 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
RA Capital Management, L.P. | 1,606,859 5.600% |
1,606,859 (New Position) |
Filing |